1. Home
  2. FSP vs RLYB Comparison

FSP vs RLYB Comparison

Compare FSP & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Street Properties Corp.

FSP

Franklin Street Properties Corp.

HOLD

Current Price

$0.63

Market Cap

72.4M

Sector

Real Estate

ML Signal

HOLD

Logo Rallybio Corporation

RLYB

Rallybio Corporation

HOLD

Current Price

$15.90

Market Cap

75.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSP
RLYB
Founded
1981
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.4M
75.9M
IPO Year
2001
2021

Fundamental Metrics

Financial Performance
Metric
FSP
RLYB
Price
$0.63
$15.90
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
552.7K
55.9K
Earning Date
04-28-2026
05-11-2026
Dividend Yield
6.34%
N/A
EPS Growth
15.69
N/A
EPS
N/A
N/A
Revenue
$107,162,000.00
$858,000.00
Revenue This Year
$17.91
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
43.00
52 Week Low
$0.50
$0.30
52 Week High
$1.82
$17.57

Technical Indicators

Market Signals
Indicator
FSP
RLYB
Relative Strength Index (RSI) 55.65 66.27
Support Level $0.58 $0.56
Resistance Level $0.70 $17.57
Average True Range (ATR) 0.06 0.60
MACD 0.02 -0.18
Stochastic Oscillator 51.01 52.77

Price Performance

Historical Comparison
FSP
RLYB

About FSP Franklin Street Properties Corp.

Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: